GlobeNewswire Inc | Aug 5, 2020 07:00AM EDT

August 05, 2020

GAITHERSBURG, Md., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the three and six months ended June 30, 2020 and its business outlook before the market open and host a conference call on Wednesday, August 12, 2020.

Conference Call DetailsDate: Wednesday, August 12Time: 8:30 am Eastern TimeDomestic: 877-423-9813International: 201-689-8573Conference ID: 13706947Webcast: http://public.viavid.com/index.php?id=140748

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID), anthrax (NasoShield) and influenza (NasoVAX); an intranasal immune modulating therapeutic for COVID-19 (T-COVID); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell). For more information on Altimmune, please visit www.altimmune.com.

Investor Contacts: Will Brown Ashley R. RobinsonChief Financial Officer LifeSci Advisors, LLCPhone: 240-654-1450 617-430-7577wbrown@altimmune.com arr@lifesciadvisors.com Media Contacts: Warren Rizzi Sard Verbinnen & Co. Phone: 212-687-8080 altimmune-svc@sardverb.com